Literature DB >> 23475501

Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).

Friedrich Modde1, Putri Andina Agustian, Juliane Wittig, Maximilian Ernst Dämmrich, Vinzent Forstmeier, Udo Vester, Thurid Ahlenstiel, Kerstin Froede, Ulrich Budde, Anne-Margret Wingen, Anke Schwarz, Svjetlana Lovric, Jan Thomas Kielstein, Carsten Bergmann, Nadine Bachmann, Mato Nagel, Hans Heinrich Kreipe, Verena Bröcker, Clemens Luitpold Bockmeyer, Jan Ulrich Becker.   

Abstract

Atypical haemolytic-uremic syndrome (aHUS) is, in most cases, due to hereditary or acquired defects in complement regulation and a life-threatening disease. Despite the rapidly grown knowledge about the primary defects in aHUS, the pathogenesis that links complement dysregulation with microthrombus formation in aHUS is still unknown. Thus, we examined the glomerular microvascular expression of pro- and antithrombotic genes. Glomeruli were microdissected from 12 archival paraffin-embedded biopsies with aHUS and from seven control biopsies. Glomerular mRNA expression was quantified by single real-time PCR reactions after preamplification. In addition immunostains were performed for plasminogen activator inhibitor 1 (PAI-1) and for tissue plasminogen activator (tPA). Results were compared between cases and controls and with clinical data. Glomeruli in aHUS had increased mRNA expression of antifibrinolytic, prothrombotic PAI-1, antithrombotic thrombomodulin (THBD) and CD73 and decreased expression of profibrinolytic, antithrombotic tPA compared to controls. Impaired fibrinolysis due to increased microvascular expression of the antifibrinolytic PAI-1 in combination with the decreased expression of the profibrinolytic tPA seems to be a final common pathway in renal thrombotic microangiopathy that is also effective in aHUS. The concomitant induction of antithrombotic transcripts likely indicates counterregulatory efforts, demonstrating that the capillary bed is not a passive victim of complement attack. Future research should investigate if and how complement activation could induce the reported shift in the expression of PAI-1 and tPA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475501     DOI: 10.1007/s00428-013-1386-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  60 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

2.  The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning.

Authors:  P J van Kesteren; T Kooistra; M Lansink; G J van Kamp; H Asscheman; L J Gooren; J J Emeis; U M Vischer; C D Stehouwer
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

3.  C5a induces tissue factor activity on endothelial cells.

Authors:  K Ikeda; K Nagasawa; T Horiuchi; T Tsuru; H Nishizaka; Y Niho
Journal:  Thromb Haemost       Date:  1997-02       Impact factor: 5.249

Review 4.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 5.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

6.  Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Elizabeth J Kemp; Elizabeth Mayland; Robin J Winney; Jeremy S Duffield; Graham Warwick; Anna Richards; Roy Ward; Judith A Goodship; Timothy H J Goodship
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

7.  C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils.

Authors:  Johann Wojta; Christoph Kaun; Gerlinde Zorn; Minoo Ghannadan; Alexander W Hauswirth; Wolfgang R Sperr; Gerhard Fritsch; Dieter Printz; Bernd R Binder; Georg Schatzl; Joerg Zwirner; Gerald Maurer; Kurt Huber; Peter Valent
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Plasma inhibitor of glomerular fibrinolysis in the hemolytic-uremic syndrome.

Authors:  J M Bergstein; U Kuederli; N U Bang
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

Review 9.  New insights into the molecular mechanisms of the fibrinolytic system.

Authors:  D C Rijken; H R Lijnen
Journal:  J Thromb Haemost       Date:  2008-11-08       Impact factor: 5.824

Review 10.  Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?

Authors:  Karl Desch; David Motto
Journal:  J Am Soc Nephrol       Date:  2007-08-08       Impact factor: 10.121

View more
  5 in total

1.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Loss of Krüppel-like factor 6 cripples podocyte mitochondrial function.

Authors:  Jeffrey B Kopp
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

3.  TTP or complement-mediated TMA or both? A rare diagnosis and report of a novel plasminogen gene variant.

Authors:  Nishant R Tiwari; Sankalp Arora; Aditya G Tolat; Saad Paul Shaheen; Vivek R Sharma
Journal:  Ann Hematol       Date:  2021-07-16       Impact factor: 3.673

4.  Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1.

Authors:  Olivia May; Nicolas S Merle; Anne Grunenwald; Viviane Gnemmi; Juliette Leon; Cloé Payet; Tania Robe-Rybkine; Romain Paule; Florian Delguste; Simon C Satchell; Peter W Mathieson; Marc Hazzan; Eric Boulanger; Jordan D Dimitrov; Veronique Fremeaux-Bacchi; Marie Frimat; Lubka T Roumenina
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

5.  Minor Role of Plasminogen in Complement Activation on Cell Surfaces.

Authors:  Satu Hyvärinen; T Sakari Jokiranta
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.